Pancreatic Pseudocyst: Therapeutic Dilemma by Khanna, A. K. et al.
Hindawi Publishing Corporation
International Journal of Inﬂammation
Volume 2012, Article ID 279476, 7 pages
doi:10.1155/2012/279476
Review Article
Pancreatic Pseudocyst: Therapeutic Dilemma
A.K. Khanna,SatyendraK.Tiwary,andPuneetKumar
Department of General Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India
Correspondence should be addressed to A. K. Khanna, akhannabhu@gmail.com
Received 15 September 2011; Accepted 17 February 2012
Academic Editor: Derek O’Reilly
Copyright © 2012 A. K. Khanna et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pancreatic pseudocyst develops in both acute and chronic pancreatitis. It is an entity likely to either remain asymptomatic or
develop devastating complications. Despite being diagnosed easily, treatment exercise is still at crossroads whether in the form of
internal or external drainage or endoscopic, laparoscopic, or open intervention with a good radiological guidance. The therapeutic
dilemma whether to treat a patient with a pancreatic pseudocyst, as well as when and with what technique, is a diﬃcult one. This
paper is intended to get information about diagnostic and therapeutic exercises most appropriate for acute and chronic pancreatic
pseudocyst.
1.Background
The ﬁrst description of pseudopancreatic cyst dates back
almost two and half centuries to 1761 A.D. by Cannon et
al. [1]. The management of cystic changes of the pancreas is
an old problem. Eugene Opie, at the beginning of twentieth
century, was the ﬁrst to distinguish true pancreatic cysts,
which are, by deﬁnition, lined by epithelium, from pseudo-
cysts, which are surrounded by a wall composed of collagen
and granulation tissue. More than two centuries after the
ﬁrst description, some clear consensus and guidelines were
evolved in the Atlanta classiﬁcation of 1993 [2]. The Atlanta
classiﬁcation consists of four distinct disease entities: acute
ﬂuid collections that develop early in the course of acute
pancreatitis and do not yet have a cyst wall; acute pancreatic
pseudocysts, which arise as sequelae of acute pancreatitis or
trauma, and whose wall consists of granulation tissue and
extracellular matrix; chronic pancreatic pseudocysts, which
arise as sequelae of chronic pancreatitis and are likewise
surrounded by a wall; pancreatic abscesses, which are intra-
abdominal collections of pus immediately adjacent to the
pancreas, without any large areas of necrosis. Acute ﬂuid
collections, pancreatic pseudocysts, and pancreatic abscesses
can be distinguished from one another by the history,
imaging studies of the wall of the abnormality and its
contents, and, if necessary, a needle aspiration of the content
[2].
2.Introduction
Pseudocysts are formed after acute as well as chronic pancre-
atitis but more common after acute exacerbations of chronic
pancreatitis than acute pancreatitis. There is lack of data
containing randomized case-control studies, but numerous
caseseriesandreportsindicatethatpancreaticinjuryleadsto
pseudocystformation.Pancreaticpseudocystsoftenariseasa
complicationofacuteorchronicpancreatitis.Theprevalence
of pancreatic pseudocysts in acute pancreatitis has been
reported to range from 6% to 18.5% [3, 4]. The prevalence
of pancreatic pseudocysts in chronic pancreatitis range 20%
to 40% [5]. Pancreatic pseudocysts most commonly arise
in patients with alcoholic chronic pancreatitis (from 70%
to 78%) [6]. The second most common cause is idiopathic
chronic pancreatitis (from 6% to 16%), followed by biliary
pancreatitis (from 6% to 8%). The incidence of pseudocyst
is low ranging from 1.6 to 4.5% or 0.5 to 1 per 100000 adults
p e ry e a r[ 7, 8].
3. Classiﬁcation
D’Egidio and Schein, in 1991, described a classiﬁcation
of pancreatic pseudocyst based on the underlying etiology
of pancreatitis (acute or chronic), the pancreatic ductal
anatomy, and the presence of communication between the
cyst and the pancreatic duct and deﬁned three distinct types2 International Journal of Inﬂammation
of pseudocysts [9]. Type I, or acute “postnecrotic” pseudo-
cysts that occur after an episode of acute pancreatitis and are
associated with normal duct anatomy, rarely communicates
with the pancreatic duct. Type II, also postnecrotic pseudo-
cysts,whichoccursafteranepisodeofacute-on-chronicpan-
creatitis (the pancreatic duct is diseased but not strictured,
and there is often a duct-pseudocyst communication). Type
III, deﬁned as “retention” pseudocysts, occurs with chronic
pancreatitis and is uniformly associated with duct stricture
and pseudocyst duct communication.
Another classiﬁcation, based entirely on pancreatic duct
anatomy, is proposed by Nealon and Walser [10].
TypeI:normalduct/nocommunicationwiththecyst.
Type II: normal duct with duct-cyst communication.
TypeIII:otherwisenormalductwithstrictureandno
duct-cyst communication.
Type IV: otherwise normal duct with stricture and
duct-cyst communication.
T y p eV :o t h e r w i s en o r m a ld u c tw i t hc o m p l e t ec u t o ﬀ.
Type VI: chronic pancreatitis and no duct-cyst com-
munication.
Type VII: chronic pancreatitis with duct-cyst com-
munication [10].
4.Diagnosis
Pseudocyst of pancreas must be preceded by attacks of
pancreatitis in either acute or chronic form. Most of the
times, clinical, biochemical, and radiological evidence of
pancreatitis present, but still a large number of patients may
present with features of pancreatic pseudocyst without any
documentary evidence of pancreatitis. One should always
consider the possibility of a pseudocyst in a patient who has
persistentabdominalpain,anorexia,orabdominalmassafter
a case of pancreatitis. Rarely, patients present with jaundice
or sepsis from an infected pseudocyst [11]. In patients
presenting with pancreatic cyst incidentally discovered on
imaging, a crucial point is to deﬁne whether the patient
has had prior history of pancreatitis [12]. Rarely, patients
with large pancreatic pseudocyst may be asymptomatic
occasionally. Tender abdomen with palpable mass is the
positive ﬁnding on physical examination. Fever, icterus, and
pleural eﬀusion may be present in complicated pseudocyst.
If pseudocyst ruptures then features of secondary peritonitis
set in and presentation may be like septicaemic shock
[11]. The diagnosis of a pancreatic pseudocyst is usually
established by imaging studies, among which transabdomi-
nal ultrasonography is important as an initial investigation
[13]. Computerized tomography (CT) is often the imaging
method of choice, with 82% to 100% sensitivity and 98%
speciﬁcity [14].
Biochemical parameters have limited role in diagnosis.
Amongremarkableparametersareserumamylaseandserum
lipase, which will be elevated in most cases. Liver functions
are normally unchanged but may be deranged in cases where
obstruction to the biliary tract occurs. Another thing to
be considered is strong possibility of biliary peritonitis if
liver parameters deranged. Other inﬂammatory marker C-
reactive protein is raised and is of prognostic signiﬁcance
only. Elevated triglycerides and low serum calcium are
indirect indictors of panreatic pseudocyst.
Diﬀerential diagnosis of pancreatic pseudocyst always
may be of two possibilities either intrapancreatic lesions or
extrapancreatic lesions.
Intrapancreatic diseases mimicking pancreatitis are:
(1) pancreatitis (acute and chronic),
(2) pancreatic necrosis,
(3) pancreatic abscess,
(4) adenocarcinoma of pancreas,
(5) cystic neoplasm of pancreas,
(6) pancreatic artery pseudoaneurysm.
Extrapancreatic diseases mimicking pancreatitis are
(1) peptic ulcer disease,
(2) acute cholecystitis and cholelithiasis,
(3) gastric cancer,
(4) abdominal aortic aneurysm,
(5) ovarian cysts and carcinoma,
(6) acute myocardial infarction,
(7) pneumonia,
(8) intestinal obstruction,
(9) intestinal ischemia.
Among diﬀerent imaging modalities, ultrasound (USG)
is the foremost diagnostic tool and also useful pointer of
diagnosis in most of the cases. It may be used in
(a) transabdominal USG,
(b) colour doppler study,
(c) duplex scanning,
(d) endoscopic USG.
Pancreatic pseudocyst appears as anechoic structure
usually round or oval and surrounded by a smooth wall
associated with distal acoustic enhancement on US exami-
nation. They are well deﬁned and round or oval, and they are
contained within a smooth wall. During the early phases of
their development, pseudocysts can appear more complex,
with varying degrees of internal echoes. If the earliest
detection missed sometimes it may be due to excessive bowel
gas.Whennecroticdebrisorhemorrhagepresentsinsidecyst
or infection sets in then the interpretation on USG may be
diﬃcult. Color Doppler or duplex scanning should always
be performed in cystic lesions to ensure that the lesion in
question is not a giant pseudoaneurysm. Sensitivity rates
for US in the detection of pancreatic pseudocysts are from
75% to 90%. Therefore, US is inferior to CT, which has a
sensitivity rate of 90%–100%. US has several limitations, as
compared with CT, in the initial diagnosis of a pseudocyst:International Journal of Inﬂammation 3
the presence of overlying bowel gas decreases the sensitivity
of US, and unlike CT, US examinations are highly operator
dependent [15].
A thick-walled, rounded, and ﬂuid-ﬁlled mass adjacent
to the pancreas on an abdominal CT scan in a patient with
a history of acute or chronic pancreatitis is virtually pathog-
nomonic for pancreatic pseudocyst. In acute manifestations
when ileus or excessive gas shadow or bowel obstruction
is a problem in USG evaluation, CT scan is deﬁnitely
better and is purposeful in diagnosing pseudocyst. It is
almost diagnostic and no other supplementary investigation
that is required to conﬁrm the diagnosis. Major advantage
of CT scan is the detection of an objective and detailed
anatomy as well as pathology. In addition to pancreas,
extrapancreatic pathology as well as status of adjoining
organs, for example, gallbladder, liver, common bile duct,
stomach, and duodenum can be perfectly assessed. Contrast-
enhanced CT is now the primary tool of investigation for
initial diagnosis of pancreatic pseudocysts. USG should be
done for the followup of asymptomatic pseudocysts or when
diagnosis is uncertain. The only major limitation of CT scan
isthatitisunablet odiﬀerentiatecysticneoplasmofpancreas
from pseudocyst, and the main pathology to be missed is
mucinous cystadenomas and intraductal papillary mucinous
cystadenoma (IPMN) [16].
MRI and MRCP are accurate and sensitive diagnostic
aids for deﬁning the anatomy of duct better than any other
diagnostic tool. But these are not used routinely as adequate
information is obtained in maximum cases by CT, and very
rarely ductal anatomy is needed to be calibrated with too
much precision and MRI/MRCP is required. Pancreatic duct
and biliary system are best visualized in detail although
interpretation of integrity of pancreatic duct may be diﬃcult
[17]. MRCP techniques can also depict subtle branch-chain
dilatation in chronic pancreatitis. MRIis also highly sensitive
to the detection of bleeding with complex ﬂuid collections.
The role of endoscopic retrograde cholangiopancreatog-
raphy (ERCP) is limited to some extent for therapeutic
intervention rather than diagnostic purpose. It may help
in planning an intervention after the increased use of
endoscopic USG its role is gradually decreasing.
Endoscopic ultrasound (EUS) is a test of choice to diﬀer-
entiate between cystic neoplasms of pancreas from pseudo-
cyst. EUS is usually used as a secondary test to further evalu-
ate pancreatic cyst detected by other imaging modality (US,
CT or MRI). For the distinction of acute ﬂuid collections
from pancreatic abscesses and acute pancreatic pseudocysts,
endosonography (EUS) has the highest sensitivity (93% to
100%) and speciﬁcity (92% to 98%). The diagnostic punc-
ture of a pseudocyst under EUS guidance helps distinguish
cystic malignancies from pseudocysts. A malignant lesion is
more likely present when the carcinoembryogenic antigen
(CEA) value exceeds 192ng/mL and when the cyst contents
are highly viscous [18].
Visualization of the pancreas via EUS provides high
quality images due to the close proximity analysis, which are
helpfultodetectmalignancy.AnelevatedCEAlevelonFNAC
within the cyst ﬂuid strongly suggests mucinous lesion [19,
20]. Amylase levels are usually high in pseudocysts and low
in serous cystadenoma of the ultrasound transducer to the
areaofinterest.Criteriasuggestiveofcysticneoplasminclude
a cyst wall thickness of greater than 3mm, macroseptation
(all cystic components more than 10mm), the presence of a
mass or nodule, and cystic dilation of the main pancreatic
duct [19–21].
Aspiration of cyst ﬂuid under EUS guidance and bio-
chemical analysis with molecular analysis helps in diﬀeren-
tiating diﬀerent cystic neoplasms of pancreas. Mutational
changes and DNA content point towards malignancy.
5. Treatment
Treatment of pseudopancreatic cyst comprises two aspects:
supportive care or medical management and deﬁnitive care
or surgical drainage.
Intravenous ﬂuids, analgesics, and antiemetics are the
basic requirements. Low-far diet is given to patients who
tolerate and intake. In patients with low or poor oral
intake, support can be provided via nasoenteral feeding or
total parenteral nutrition (TPN). To date, no studies have
compared these two approaches in the seating of pancreatic
pseudocyst, and the choice is based on availability and local
preferences. If one can extrapolate from studies comparing
the two modalities in the seating of acute necrotizing
pancreatitis, one can expect that jejunal feeding will be
related with fewer complications (infection) but may not be
a b l et op r o v i d ea sm u c hc a l o r i e sa sT P N .
T h er o l eo fo c t r e o t i d ei ss t i l ld u b i o u sa st h i sh a sn o t
been tested much with strong evidence in the literature.
The rationale of using octreotide as a therapy for pancreatic
pseudocyst is that it will decrease pancreatic secretions and
aid in pseudocyst resolution. Unfortunately, this strategy has
not been rigorously tested and only a handful of case series
have been published [22, 23].
Most pseudocysts resolve with supportive medical care.
Vitas and Sarr followed over a period of 5 years 114 patients
with the diagnosis of pancreatic pseudocyst [24]. Forty-six
patients underwent primary operative therapy, with 13%
undergoing emergency operations for pseudocyst-related
complications.Morbidityoccurredin26%ofpatients(emer-
gency operations, 67%; elective procedures, 10%) without
any mortality. The remaining 68 patients were initially
treated with a nonoperative expectant approach. Severe and
life-threatening complications in this group (followup for a
mean of 46month) occurred in only six patients (9%); 19
patients eventually underwent elective operations directed
at either the pseudocyst or other complications related to
pancreatitis. Overall, in patients managed by a nonoperative
approach, resolution of the pseudocyst occurred in 57%
of the 24 patients with satisfactory radiographic followup,
with 38% resolving more than 6 months after diagnosis.
Although patients eventually undergoing operation tended
to have larger pancreatic pseudocysts than the patients
managed successfully nonoperatively (6.9cm versus 4.9cm),
no serious complications occurred in seven patients with
pancreatic pseudocysts greater than 10cm who were treated
expectantly [24].4 International Journal of Inﬂammation
Large-sized and long-standing cysts are not likely to
respond on conservative treatment and more likely to
have complications during the course of the disease. Mor-
bidity and mortality are more commonly found in this
group. These patients need surgical intervention and usually
managed surgically. But some studies say that size and
duration never matter, and actually these patients too have
excellent surgical results and do well. There are two deﬁnite
conclusions that the presence and the severity of symptoms
and complications are determinants of prognosis and course
in pancreatitis [25–27].
6. Drainage Procedures
Most of the symptomatic and complicated pancreatic pseu-
docysts need intervention in any form during the course
of the disease. Intervention options are either guided endo-
scopically, radiologically, laparoscopically, or open/direct.
To date, no prospective controlled studies have compared
directly percutaneous, surgical, and endoscopic drainage
approaches. As a result, the management varies based
on local expertise, but in general endoscopic drainage is
becoming the preferred approach followed by laparoscopic
approach.
There is no consensus regarding methods of intervention
in pancreatic pseudocyst although there is no controversy
with conservative treatment. Minimal intervention with
maximal conservative approach remains the most widely
acceptable option of therapeutic intervention in pancre-
atic pseudocyst. Small sized asymptomatic cysts need no
intervention at all. Asymptomatic large-sized cyst should be
intervened after six weeks only and in the meantime is must
be under close monitoring to detect the earliest symptoms
or complications. Only in symptomatic cases or if any
complication develops, intervention is required before six
weeks. Cyst of any size should be intervened once it becomes
symptomatic or if complications develop irrespective of
duration, size, or site. So two things are important determi-
nantstheregardingplanofmanagement:sizewhenitismore
than ﬁve cm and duration when it is more that six weeks.
6.1. External Drainage. External drainage can be achieved
radiologically by using CT or US guidance. In this technique,
a drainage pigtail catheter is placed percutaneously into the
ﬂuid cavity, and the ﬂuid is drained. Three-dimensional
ultrasonography has been reported useful for the guidance
of catheters into cyst cavities and avoiding vessels. When the
drainage output becomes minimal, the catheter is removed.
Contrast injection into the cyst cavity will demonstrate the
size of the remaining cavity, and this ﬁnding can be used
to monitor the progress. This technique is successful in
resolving pseudocysts, but it has a high risk of infections.
This technique is deﬁnitely a failure if the catheter tends
to block repeatedly. It tends to create signiﬁcant discomfort
to the patient. Furthermore, the catheter tends to clog and
may require repositioning and exchange. The reported long-
term success rate of pseudocyst resolution for US-guided
pseudocyst drainage is around 50%. Unsuccessful drainages
are usually caused by large ductal leaks or obstruction of
the main pancreatic duct. Percutaneous catheter drainage is
contraindicated in patients who are poorly compliant and
cannot manage a catheter at home. It is also contraindicated
in patients with strictures of the main pancreatic duct and in
patients with cysts containing bloody or solid material [28–
30].
6.2. Surgical Drainage. In cases of failure of external percuta-
neous drainage radiologically, this approach is applied either
by open method or by laparoscopy. It can be a good option
for the patients who cannot tolerate endoscopic drainage.
Stoma is created between the most dependent part of the
cystandtheadjoiningstomach,jejunum,orileumtoprovide
eﬀective drainage.
For surgical drainage, either lap or open method can
be opted as both are eﬀective for relief, but laparoscopic
approach deﬁnitely carries low morbidity and mortality as
compared to open techniques. Surgical drainage, which is
increasingly done laparoscopically with a cholecystectomy if
needed is the preferred mode then open approach.
External drainage of pseudocyst should only be carried
outincaseofemergencyreliefofseveresymptomsandsepsis.
Otherwise, EUS or surgical drainage are the procedures of
choice. Blind external drainage when duct status is unsure
results in diﬃcult-to-manage pancreatic ﬁstulae [31].
6.3. Endoscopic Drainage. Endoscopic drainage of pseudo-
cystsisbecomingthepreferredtherapeuticapproachbecause
it is less invasive than surgery. The intervention done is
minimal and avoids the need for external drain and has
a high long-term success rate. Internal drainage is accom-
plished with either a transpapillary approach with ERCP
or direct drainage across the stomach or duodenal wall. A
transpapillary approach is preferable when the pseudocyst
communicates with the main pancreatic duct, usually in the
gene of the pancreatic duct. This approach is also successful
for patients with pancreatic duct disruption. The endoscopic
approach is guided by the presence of a bulge into the lumen
of the stomach or duodenum in order to determine the entry
site for catheterization. This approach has several inherent
risks, including missing the pseudocyst, injuring intervening
vessels, and suboptimal placement of the drainage catheter
[32]. Therapeutic echoendoscopes now make it possible to
treat pseudocysts with EUS-guided transmural stenting [33].
Several series have described the deployment of a 7 Fr stent
that is introduced with a needle-knife catheter [34]. A new
large-channel echoendoscope allows the use of 10 Fr stent
across the stomach or duodenum [35].
In a large retrospective analysis of 603 patients who were
undergoing EUS-FNA of pancreatic cysts, possible infection
developed in only a single patient. The majority of patients
in this series (90%) received antibiotic prophylaxis, most
commonly a ﬂuoroquinolone given for 3 days after the
procedure, and this may possibly explain the low infection
rate. The beneﬁt of prophylactic antibiotics before an FNA
of cystic lesions has not been evaluated by prospective
randomized studies [36].International Journal of Inﬂammation 5
The ASGE, in 2008, published the guidelines for pro-
phylactic use of antibiotics for GI endoscopy. According to
these guidelines, prophylaxis with an antibiotic, such as a
ﬂuoroquinolone, is administered before EUS-FNA of cystic
lesions along the GI tract including pancreatic cyst. Antibi-
otics may be continued for 3–5 days after the procedure
(supported by observational studies). The administration of
antibiotic prophylax, a ﬂuoroquinolone administered before
the procedure and continued for 3 days after the procedure,
is a reasonable regimen [37].
Cahen et al. concluded that endoscopic drainage is an
eﬀective treatment for pancreatic pseudocysts and oﬀers a
deﬁnitive solution in almost three-quarters of the cases.
The majority of the major complications might have been
preventedbyusingpigtailstentsinsteadofstraightstentsand
by taking a more aggressive approach to the prevention and
treatment of secondary cyst infection [38].
Final decision on EUS versus surgical drainage is impor-
tantandinterestingasthedecisionmakingdependsuponthe
proﬁle of the patient. It is important to know that multiple
procedures are sometimes necessary to ensure adequate
drainage. Also when there is a large amount of solid debris,
EUS drainage does not give good results. There has been
signiﬁcant technical advancement in EUS-guided drainage
procedures with improved equipments and skill base. It is
certain that EUS drainage will be more and more a preferred
option over surgical drainage in the future too.
7. Complications
Pancreatic pseudocyst needs close followup to early detect
the most dreadful complications, which may be devastating
if it remain unrecognized for long.
(A) Infection: infection occurs either spontaneously or
after therapeutic or diagnostic manipulations. While
infected pseudocyst can initially be treated with
conservative means, a majority of patients will
require intervention. Traditionally, surgery has been
the preferred modality but endoscopic treatment is
gaining acceptance. An external drainage may be
necessary in selected situations such as when there is
evidenceofgrosssepsisandthepatientistoounstable
to undergo surgical or endoscopic drainage [39].
(B) Hemorrhage: hemorrhage can greatly complicate the
course of a pseudocyst and can be devastating [40].
The morbidity and mortality is very high because
it can appear without warning and is usually due
to erosion of a major vessel in the vicinity of the
pseudocyst. If not recognized immediately, life of the
patient may be jeopardized. Interventional radiology
canplayaninvaluablerolebothinlocatingthesource
of bleeding and in embolisation of the bleeding vessel
[41]. Without prior information of the bleeding
point, surgical exploration can be hazardous and
challenging.
(C) Splenic infarction and thrombosis: complications of
pseudocyst include massive hemorrhage into the
pseudocyst,sepsiswithsplenicinfarction,andsplenic
vein thrombosis. The diagnosis of intrasplenic pseu-
docyst, based on clinical ﬁndings alone, is diﬃcult to
arrive at but should be suggested by the presence of
a mass in the left upper quadrant. Sonography and
computerized axial tomography may be particularly
helpful in conﬁrming splenic involvement. Selective
celiac arteriography should be performed whenever
splenic involvement is suggested in order to conﬁrm
the diagnosis and to search for pseudoaneurysm
formation. Urgent surgical intervention is usually
warranted in view of the high incidence of seri-
ous complications and the propensity toward rapid
clinical deterioration. Resection of the pseudocyst
by splenectomy and distal pancreatectomy is the
treatment of choice [42].
(D) Rupture: rupture of a pseudocyst can have either
a favorable or an unfavorable outcome, and this
dependsonwhetheritrupturesintothegastrointesti-
nal tract, into the general peritoneal cavity, or into
the vascular system. Rupture into the gastrointestinal
tract either results in no symptoms or leads to
melaena or hematemesis that usually requires urgent
measures. Rupture into the general peritoneal cavity
results in features of peritonitis and occasionally
hemorrhagic shock. Emergent surgical exploration is
usually required. While an internal drainage should
always be aimed for, usually a thorough abdominal
lavage and external drainage are all that can be
achieved safely [43, 44].
(E) Biliarycomplications:biliarycomplicationsoccurdue
to a large cyst in the pancreatic head region obstruct-
ingthecommonbileductandresultinginobstructive
jaundice. Therapeutic endoscopy with short-term
biliary stenting is valuable in this situation. It can
be retained until either the pseudocyst resolves or is
treated by intervention [45, 46].
(F) Portal hypertension: portal hypertension can result
from compression or obstruction of the splenic
vein/portal vein either by the cyst alone or by the cyst
in conjunction with underlying chronic pancreatitis.
In this situation, surgery appears to be the only
treatment modality available, and an appropriate
surgical procedure can eﬀectively treat this form of
portal hypertension [47].
(G) Gastric outlet obstruction: pseudocysts around the
head of the pancreas are likely to cause gastric
outlet obstruction. Once the features of gastric outlet
obstruction develop, it needs certainly intervention
and decompression or drainage of the cyst.
8. Conclusion
Pancreatic pseudocysts are the most common cystic lesions
of the pancreas, accounting for 75%–80% of such lesions.
The most common symptoms are abdominal pain, nau-
sea, and vomiting, although they can be asymptomatic.6 International Journal of Inﬂammation
Abdominal CT is an excellent choice for initial imaging. EUS
plays an important role in diﬀerentiating pseudocyst from
other cystic lesions of the pancreas and can greatly assist
in transmural endoscopic drainage. Initial management
consists of supportive care. Persistent symptoms and the
development of complications warrant invasive interven-
tion. The endoscopic and minimally invasive therapeutic
procedures for the drainage of pancreatic pseudocysts are
superior to open surgical techniques with respect to their
success, morbidity, and mortality rates, but they cannot
always be performed. In making treatment decisions, it
is important to recall that 50% of pancreatic pseudocysts
do not require any intervention and can be successfully
managed by a wait-and-watch approach. Laparoscopic and
endoscopic drainages have comparable success rates, while
that of transcutaneous drainage are somewhat worse. Thus,
the choice of technique depends very heavily on the experi-
ence of the treatment center. The surgical, percutaneous, and
endoscopic pseudocyst drainage procedures have not been
directly compared in high-quality prospective randomized
studies and the preferred approach varies based on patient
preferences and local expertise.
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